Ketorolac intranasal - Egalet

Drug Profile

Ketorolac intranasal - Egalet

Alternative Names: Ketorolac trometamol intranasal; Ketorolac trometamol nasal spray; Ketorolac tromethamine intranasal; Ketorolac tromethamine nasal spray; ROX-828; ROX-888; Sprix

Latest Information Update: 08 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ROXRO PHARMA
  • Developer Egalet; Luitpold Pharmaceuticals; OraPharma; ROXRO PHARMA
  • Class 2 ring heterocyclic compounds; Carboxylic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrroles; Small molecules
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute pain
  • Phase III Postoperative pain
  • Discontinued Migraine

Most Recent Events

  • 03 Jan 2018 Egalet and OraPharma agree to co-promote ketorolac intranasal in USA
  • 03 Jan 2018 Ketorolac intranasal is no longer licensed to Septodont in USA
  • 07 Jun 2017 Egalet partners with Ascend Therapeutics to co-promote ketorolac intranasal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top